nevirapine has been researched along with Malaria in 14 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
Excerpt | Relevance | Reference |
---|---|---|
" However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART." | 9.19 | Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014) |
"Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria." | 8.31 | Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023) |
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed." | 7.88 | Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018) |
"We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations." | 7.83 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016) |
"HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)." | 7.81 | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015) |
"In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients." | 5.30 | Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction? ( Abdullahi, ST; Bakare-Odunola, MT; Bolarinwa, RA; Khoo, S; Olagunju, A; Olarewaju, OJ; Owen, A; Soyinka, JO, 2019) |
" However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART." | 5.19 | Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014) |
"Artemether-lumefantrine and nevirapine-based antiretroviral therapy (ART) are the most commonly recommended first-line treatments for malaria and HIV, respectively, in Africa." | 5.15 | Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. ( Barnes, KI; Cohen, K; Kredo, T; Maartens, G; Mauff, K; Smith, P; Van der Walt, JS; Wiesner, L, 2011) |
"Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria." | 4.31 | Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023) |
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed." | 3.88 | Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018) |
"We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations." | 3.83 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016) |
"HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)." | 3.81 | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015) |
"Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity." | 3.80 | Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ( Adedeji, WA; Adewole, IF; Akinola, IT; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, FA; Lindegardh, N; Ma, Q; Morse, GD; Murphy, RL; Ojengbede, O; Parikh, S; Scarsi, KK; Taiwo, B; Tarning, J, 2014) |
"This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms of HIV-infected adults: efavirenz-based treatment arm (EFV-arm) n = 66, nevirapine-based treatment arm (NVP-arm) n = 128, and control-arm n = 75, with uncomplicated malaria." | 3.80 | Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. ( Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngasala, B; Sasi, PG, 2014) |
"Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions." | 2.77 | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ( Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012) |
" However, pharmacokinetic knowledge is lacking for specific populations, especially patients with neglected tropical diseases and severe malnutrition." | 2.72 | Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. ( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Verrest, L; Wilthagen, EA, 2021) |
" There were no clinically relevant toxicities nor adverse events in both control and test arms." | 1.56 | Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. ( Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 11 (78.57) | 24.3611 |
2020's | 3 (21.43) | 2.80 |
Authors | Studies |
---|---|
Kay, K | 1 |
Goodwin, J | 1 |
Ehrlich, H | 1 |
Ou, J | 1 |
Freeman, T | 1 |
Wang, K | 1 |
Li, F | 1 |
Wade, M | 1 |
French, J | 1 |
Huang, L | 1 |
Aweeka, F | 1 |
Mwebaza, N | 1 |
Kajubi, R | 1 |
Riggs, M | 1 |
Ruiz-Garcia, A | 1 |
Parikh, S | 2 |
Usman, SO | 1 |
Oreagba, IA | 1 |
Akinyede, AA | 1 |
Agbaje, EO | 1 |
Akinleye, MO | 1 |
Onwujuobi, AG | 1 |
Ken-Owotor, C | 1 |
Adeuja, O | 1 |
Ogunfowokan, T | 1 |
Kogbe, S | 1 |
Owolabi, ET | 1 |
Adeniji, H | 1 |
Busari, AW | 1 |
Hassan, OO | 1 |
Abideen, G | 1 |
Akanmu, AS | 1 |
Verrest, L | 1 |
Wilthagen, EA | 1 |
Beijnen, JH | 1 |
Huitema, ADR | 1 |
Dorlo, TPC | 1 |
Haaland, RE | 1 |
Otieno, K | 1 |
Martin, A | 1 |
Katana, A | 1 |
Dinh, C | 1 |
Slutsker, L | 1 |
Menendez, C | 1 |
Gonzalez, R | 1 |
Williamson, J | 1 |
Heneine, W | 1 |
Desai, M | 1 |
Abdullahi, ST | 1 |
Olagunju, A | 1 |
Soyinka, JO | 1 |
Bolarinwa, RA | 1 |
Olarewaju, OJ | 1 |
Bakare-Odunola, MT | 1 |
Owen, A | 1 |
Khoo, S | 2 |
Scarsi, KK | 1 |
Fehintola, FA | 1 |
Ma, Q | 1 |
Aweeka, FT | 1 |
Darin, KM | 1 |
Morse, GD | 1 |
Akinola, IT | 1 |
Adedeji, WA | 1 |
Lindegardh, N | 2 |
Tarning, J | 2 |
Ojengbede, O | 1 |
Adewole, IF | 1 |
Taiwo, B | 1 |
Murphy, RL | 1 |
Akinyinka, OO | 1 |
Kakuru, A | 1 |
Achan, J | 1 |
Muhindo, MK | 1 |
Ikilezi, G | 1 |
Arinaitwe, E | 1 |
Mwangwa, F | 1 |
Ruel, T | 1 |
Clark, TD | 1 |
Charlebois, E | 1 |
Rosenthal, PJ | 1 |
Havlir, D | 1 |
Kamya, MR | 1 |
Tappero, JW | 1 |
Dorsey, G | 1 |
Maganda, BA | 3 |
Minzi, OM | 3 |
Kamuhabwa, AA | 3 |
Ngasala, B | 1 |
Sasi, PG | 1 |
Ngaimisi, E | 2 |
Aklillu, E | 2 |
Kredo, T | 1 |
Mauff, K | 1 |
Van der Walt, JS | 1 |
Wiesner, L | 1 |
Maartens, G | 1 |
Cohen, K | 1 |
Smith, P | 1 |
Barnes, KI | 1 |
Porter, KA | 2 |
Cole, SR | 1 |
Eron, JJ | 2 |
Zheng, Y | 1 |
Hughes, MD | 1 |
Lockman, S | 2 |
Poole, C | 1 |
Skinner-Adams, TS | 2 |
Hosseinipour, M | 1 |
Shaffer, D | 2 |
D'Amico, R | 2 |
Sawe, FK | 1 |
Siika, A | 2 |
Stringer, E | 2 |
Currier, JS | 2 |
Chipato, T | 2 |
Salata, R | 2 |
McCarthy, JS | 2 |
Meshnick, SR | 2 |
Butterworth, AS | 1 |
Sawe, F | 1 |
Hosseinipour, MC | 1 |
Byakika-Kibwika, P | 1 |
Lamorde, M | 1 |
Mayito, J | 1 |
Nabukeera, L | 1 |
Namakula, R | 1 |
Mayanja-Kizza, H | 1 |
Katabira, E | 1 |
Ntale, M | 1 |
Pakker, N | 1 |
Ryan, M | 1 |
Hanpithakpong, W | 1 |
de Vries, PJ | 1 |
Back, D | 1 |
Merry, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children[NCT00978068] | Phase 3 | 176 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults[NCT00790881] | Phase 4 | 36 participants (Anticipated) | Interventional | 2008-10-31 | Completed | ||
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505] | Phase 3 | 745 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy
Intervention | Cummulative Risk Percentage (Number) |
---|---|
LPV/r + 2 NRTIs | 14.0 |
NVP or EFV + 2 NRTIs | 40.8 |
To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy
Intervention | Cumulative Risk Percentage (Number) |
---|---|
LPV/r + 2 NRTIs | 28.1 |
NVP or EFV + 2 NRTIs | 54.2 |
To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula. (NCT00978068)
Timeframe: Enrollment to 6 months follow up
Intervention | Cumulative Risk Percentage (Number) |
---|---|
LPV/r + 2 NRTIs | 40.7 |
NVP or EFV + 2 NRTIs | 52.5 |
(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study
Intervention | Episodes/ Person-Yr at Risk (Number) |
---|---|
Group 1 | 0.024 |
Group 2 | 0.026 |
(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study
Intervention | Episodes/ Person-Yr at Risk (Number) |
---|---|
Group 1: LPV/r + 2 NRTIs | 1.32 |
Group 2: Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTIs | 2.25 |
The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL). (NCT00978068)
Timeframe: 28 days after antimalarial therapy
Intervention | % uncomplicated malaria episodes w/ AEs (Number) |
---|---|
LPV/r + 2 NRTIs | 71.0 |
NVP or EFV + 2 NRTIs | 79.3 |
Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 6 |
NVP/LPV_r | 4 |
NoNVP/NVP | 19 |
NoNVP/LPV_r | 26 |
The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 15 |
NVP/LPV_r | 0 |
NoNVP/NVP | 35 |
NoNVP/LPV_r | 0 |
Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 32 |
NVP/LPV_r | 10 |
NoNVP/NVP | 42 |
NoNVP/LPV_r | 50 |
Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.
Intervention | participants (Number) |
---|---|
NVP/NVP | 20 |
NoNVP/NVP | 51 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.
Intervention | cells/mm^3 (Median) | |
---|---|---|
Week 48 CD4 count change from randomization | Week 96 CD4 count change from randomization | |
NoNVP/LPV_r | 172 | 256 |
NoNVP/NVP | 172 | 223 |
NVP/LPV_r | 201 | 278 |
NVP/NVP | 191 | 291 |
Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | Percent of participants (Number) | |
---|---|---|
week 48 percent of virologic failure or death | week 96 percent of virologic failure or death | |
NoNVP/LPV_r | 14 | 20 |
NoNVP/NVP | 14 | 17 |
NVP/LPV_r | 4 | 12 |
NVP/NVP | 23 | 31 |
Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | percent of participants (Number) | |
---|---|---|
week 48 percent of full adherence in past month | week 96 percent of full adherence in past month | |
NoNVP/LPV_r | 86 | 87 |
NoNVP/NVP | 90 | 93 |
NVP/LPV_r | 88 | 95 |
NVP/NVP | 89 | 94 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NVP/LPV_r | 60 | 84 | NA |
NVP/NVP | 12 | 12 | 60 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NoNVP/LPV_r | 12 | 36 | 132 |
NoNVP/NVP | 24 | 36 | NA |
1 review available for nevirapine and Malaria
Article | Year |
---|---|
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.
Topics: HIV Infections; Humans; Malaria; Malnutrition; Nevirapine; Pharmaceutical Preparations; Poverty | 2021 |
6 trials available for nevirapine and Malaria
Article | Year |
---|---|
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Cross-Over Studies; Cytochrome P-45 | 2019 |
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HI | 2014 |
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug | 2011 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease | 2012 |
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir | 2012 |
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin | 2012 |
7 other studies available for nevirapine and Malaria
Article | Year |
---|---|
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Comb | 2023 |
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Be | 2020 |
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo | 2018 |
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highl | 2014 |
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
Topics: Adult; Africa South of the Sahara; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, | 2014 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cyclopropanes; Drug Inter | 2015 |
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter, | 2016 |